InMode Ltd. (INMD)
Nasdaq · Healthcare · Medical Devices
$14.13+0.28%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $813M
- P/E (trailing)
- 11.7
- Forward P/E
- 10.3
- 52-week range
- $12.72 – $16.74
- 52-week change
- −6.25%
- EPS (trailing)
- $1.21
- Next earnings
- Nov 4, 2026
Fiscal year to Dec 2025
- Revenue
- $371M (−6.16%)
- Operating margin
- 23.0%
- Diluted EPS
- $1.43
- Free cash flow
- $84.3M
From the company’s annual report on SEC EDGAR.
About InMode Ltd.
InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States, Europe, Asia, and internationally. It offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. The company also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions. In addition, it offers hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation.
Headquarters: Yokne'am, Israel · 660 employees · inmodemd.com